GET DAILY SIGNALSClaritev Corporation (CTEV) Reports +9.1% Revenue Growth and Raises Full-Year Outlook
Key Takeaways
- Revenue climbed 9.1% year over year to $268.3 million, surpassing consensus estimates of roughly $256 million.
- Net loss narrowed to $61.8 million, with a diluted loss of $3.64 per share, an improvement from the $4.23 loss reported a year earlier.
- Adjusted EBITDA rose 4.4% to $162.0 million, though the adjusted EBITDA margin slipped to 60.4% from 63.1%.
- Management raised full-year 2026 guidance across revenue, adjusted EBITDA, and free cash flow, and introduced a preliminary 2027 revenue target of about $1.1 billion.
- Free cash flow remained negative at -$25.8 million, while unrestricted cash on the balance sheet stood at $10.1 million.
Earnings Context and Why It Matters
Claritev Corporation, a healthcare technology, data, and insights company, is in the middle of a multi-year transformation aimed at returning to consistent revenue growth after a period of contraction. Its third-quarter 2026 report matters because it tests whether that growth is broadening beyond payer clients and whether the company can convert accelerating top-line momentum into stronger profitability and cash generation. Investors have been closely watching claims intelligence volumes tied to the No Surprises Act, alongside the company's push into new verticals and AI-enabled workflows. With a heavily leveraged balance sheet and persistent GAAP losses, the market is equally focused on margins, free cash flow, and the credibility of management's forward guidance. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
For the third quarter ended September 30, 2026, Claritev reported revenue of $268.3 million, up 9.1% from $246.0 million in the prior-year period and ahead of consensus estimates near $256 million. Net loss narrowed to $61.8 million, or $3.64 per diluted share, compared with a net loss of $69.8 million, or $4.23 per share, a year earlier.
Adjusted EBITDA increased 4.4% to $162.0 million, but the adjusted EBITDA margin compressed to 60.4% from 63.1%, reflecting increased go-to-market investment and shifting revenue mix. Net cash provided by operating activities was $18.1 million, while free cash flow was negative $25.8 million as capital expenditures rose. The company ended the quarter with $10.1 million in unrestricted cash.
Management also raised its full-year 2026 outlook. Revenue guidance moved to $1.038 billion to $1.043 billion, adjusted EBITDA guidance to $625 million to $630 million, and free cash flow guidance to $10 million to $20 million. The company separately introduced a preliminary 2027 revenue view of at least $1.1 billion, roughly a year ahead of its prior plan.
Market Reaction and Investor Sentiment
Claritev shares advanced in the session following the release, with the stock trading higher after closing near $22.71 in the prior session. The positive reaction reflected a third consecutive quarter of raised guidance and a top-line beat that reinforced the company's growth narrative. Still, sentiment heading into the report had been mixed: the stock had pulled back sharply from its post-second-quarter highs, and short interest represented a meaningful portion of the float. The market's focus remains divided between the strengthening revenue and bookings story and concerns around margin compression, thin liquidity, and elevated leverage. The narrowed loss and higher guidance supported the bulls, but the decline in adjusted EBITDA margin and negative free cash flow kept the reaction measured.
Forward Outlook and Key Factors to Monitor
Following this report, investors will be watching whether Claritev can sustain its accelerating revenue growth while stabilizing margins. The company attributed part of the margin squeeze to deliberate go-to-market investment, so evidence that these investments are converting into bookings and revenue will be a key test in the quarters ahead.
Cash flow remains the central concern. Management's raised full-year free cash flow guidance depends on a notably strong fourth quarter, which will need to be validated by actual results rather than projections. With unrestricted cash near $10 million and revolver borrowings rising, the trajectory of free cash flow conversion is likely to matter more to investors than another revenue beat.
Finally, watch the diversification story. More than half of recent bookings came from outside the payer market, and claims intelligence growth has been a primary driver. Sustaining that breadth, delivering on the preliminary 2027 revenue target, and eventually returning payment and revenue integrity segments to growth will be important milestones as the company works to prove the durability of its turnaround.
Using Tickeron’s AI Tools in My Research
I often turn to Tickeron’s AI Screener when evaluating names like CTEV alongside peers. It lets me quickly filter for technical patterns, fundamentals, and performance metrics that align with my own criteria. This helps surface ideas and confirm whether a stock fits the broader market setup I’m tracking.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CTEV in -12.50% downward trend, declining for three consecutive days on November 03, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where CTEV declined for three days, in 272 of 297 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Aroon Indicator for CTEV entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CTEV's RSI Oscillator exited the oversold zone, 32 of 39 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 44 of 54 cases where CTEV's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on CTEV as a result. In 59 of 77 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 77%.
The Moving Average Convergence Divergence (MACD) for CTEV just turned positive on October 08, 2026. Looking at past instances where CTEV's MACD turned positive, the stock continued to rise in 38 of 45 cases over the following month. The odds of a continued upward trend are 84%.
Following a +18.69% 3-day Advance, the price is estimated to grow further. Considering data from situations where CTEV advanced for three days, in 224 of 283 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
CTEV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 19 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 25 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-1.307) is normal, around the industry mean (4.477). P/E Ratio (-1.336) is within average values for comparable stocks, (13.414). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.133). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.562) is also within normal values, averaging (6.065).
The Tickeron Price Growth Rating for this company is 77 (best 1 - 100 worst), indicating slightly worse than average price growth. CTEV’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CTEV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry ServicestotheHealthIndustry
Advertisement